Swiss National Bank Rigel Pharmaceuticals Inc Transaction History

Swiss National Bank

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	BUY	$2.22 - $3.45 $70,818 - $110,055	31,900 Added 8.56%	404,379 $1.21 Million
Q2 2021 Aug 06, 2021	SELL	$3.09 - $4.54 $31,518 - $46,308	-10,200 Reduced 2.67%	372,479 $1.62 Million
Q2 2020 Aug 05, 2020	BUY	$1.41 - $2.05 $87,279 - $126,894	61,900 Added 19.3%	382,679 $700,000
Q4 2019 Feb 06, 2020	BUY	$1.6 - $2.43 $17,120 - $26,001	10,700 Added 3.45%	320,779 $686,000
Q2 2019 Aug 02, 2019	BUY	$2.02 - $2.61 $61,610 - $79,605	30,500 Added 10.91%	310,079 $809,000
Q4 2018 Feb 13, 2019	BUY	$2.08 - $3.36 $17,472 - $28,224	8,400 Added 3.1%	279,579 $643,000
Q2 2018 Aug 09, 2018	BUY	$2.83 - $4.11 $117,668 - $170,889	41,579 Added 18.11%	271,179 $767,000
Q4 2017 Feb 07, 2018	BUY	$3.23 - $4.3 $741,608 - $987,280	229,600	229,600 $891,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.